Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Surgical Oncology

4,314 views

Published on

Published in: Health & Medicine, Technology
  • Be the first to comment

Surgical Oncology

  1. 1. SURGICAL ONCOLOGY James Taclin C. Banez, MD, FPSGS, FPCS, DPBS, DPSA
  2. 2. <ul><li>Study of neoplastic diseases: </li></ul><ul><ul><li>ONCOS = tumor LOGOS = study </li></ul></ul><ul><li>Neoplasm : </li></ul><ul><ul><li>Altered cell population characterized by an excessive, non-useful proliferation of cells that are unresponsive to normal control mechanisms and to organizing influences of adjacent tissue. </li></ul></ul>
  3. 3. Neoplasm: <ul><li>Malignant: </li></ul><ul><ul><li>Cancer cells that exhibit uncontrolled proliferation and impair the function of normal organs by local tissue invasion and metastatic spread to distant anatomic sites. </li></ul></ul><ul><li>Benign: </li></ul><ul><ul><li>Composed of normal appearing cells that do not invade locally or metastasize to other sites </li></ul></ul>
  4. 4. EPIDEMIOLOGY: <ul><li>Overall cancer death rates shows slow steady increase </li></ul><ul><li>Lower death rates during past 50yrs: </li></ul><ul><ul><li>Stomach </li></ul></ul><ul><ul><li>Uterus </li></ul></ul><ul><li>Increase death rates: </li></ul><ul><ul><li>Lung </li></ul></ul><ul><ul><li>Pancreas </li></ul></ul>
  5. 5. EPIDEMIOLOGY: <ul><li>Cancer incidence by sites and sex: </li></ul>Male Female Lung 20% Breast 27% Prostate 20% Colon & Rectum 16% Colon & Rectum 14% Lung 11% Urinary 10% Uterus 10% Leukemia & Lymphoma 8% Leukemia & Lymphoma 7% Skin, pancreas and oral 3-4% Skin, pancreas and oral 3-4%
  6. 6. EPIDEMIOLOGY: <ul><li>Cancer death by sites and sex: </li></ul>Male Female Lung 36% Lung 20% Colon & Rectum 11% Breast 18% Prostate 10% Colon & Rectum 14% Leukemia & Lymphoma 9% Leukemia & Lymphoma 9% Pancreas & Urinary 5% each Pancreas & Ovary 5% Urinary & Uterus 4% each
  7. 7. <ul><li>The most significant 5 yrs survival rates are achieved in patients w/ cancer of skin, thyroid, cervix, uterus and bladder ; w/ the lowest survival w/ pancreatic cancer </li></ul><ul><li>Females tend to have a greater number of 5yrs survival w/ cancer of any given primary site than males, reason (?) </li></ul><ul><ul><ul><li>5 yr survival female = 50% </li></ul></ul></ul><ul><ul><ul><li>5 yr survival male = 31% </li></ul></ul></ul>
  8. 8. ETIOLOGY: <ul><li>Chemical carcinogens : </li></ul><ul><ul><li>Hydrocarbons from coal tar = skin, larynx & bronchial CA </li></ul></ul><ul><ul><li>Aromatic amines = urinary tract CA </li></ul></ul><ul><ul><li>Benzene = leukemia </li></ul></ul><ul><ul><li>Asbestos = mesothelioma </li></ul></ul><ul><li>Physical carcinogens: </li></ul><ul><ul><li>Ionizing radiations = bone cancer </li></ul></ul><ul><ul><ul><li>Multiple x-rays = skin/thyroid CA </li></ul></ul></ul><ul><ul><li>Atomic bomb (Japan) = leukemia </li></ul></ul>
  9. 9. ETIOLOGY: <ul><li>Mechanical (chronic irritation): </li></ul><ul><ul><li>Marjolin’s ulcer = burn scar cancer </li></ul></ul><ul><li>Infection: </li></ul><ul><ul><li>Parasitic: </li></ul></ul><ul><ul><ul><li>Schistosomas – Liver & bladder CA </li></ul></ul></ul><ul><ul><li>Viruses: </li></ul></ul><ul><ul><ul><li>Hepatitis B – hepatocellular CA </li></ul></ul></ul><ul><ul><ul><li>Epstein-Barr virus – Burkitts lymphoma </li></ul></ul></ul><ul><ul><ul><li>Herpes simplex virus 2 – cervical CA </li></ul></ul></ul><ul><ul><ul><li>Aids </li></ul></ul></ul>
  10. 10. ETIOLOGY: <ul><li>Geographic factors: </li></ul><ul><ul><li>Inc. CA of stomach – Scandinavian, </li></ul></ul><ul><ul><li>Iceland and Japan </li></ul></ul><ul><ul><li>Inc. CA of liver – South & West Africa </li></ul></ul><ul><ul><li>Inc. CA of Nasopharynx – China </li></ul></ul><ul><ul><li>Inc. CA of urinary bladder – Egypt </li></ul></ul><ul><ul><li>Dec. CA of colon – Black/Africa </li></ul></ul><ul><ul><li>Dec. CA prostate / breast – Japan </li></ul></ul><ul><ul><li>Dec. CA of uterine/cervix – Israel/Jewish </li></ul></ul><ul><ul><li>Dec. CA of skin – Blacks </li></ul></ul><ul><li>customs & environment plays an important role in the development of CA. </li></ul><ul><li>migration of populations usually causes a shift towards the patterns of cancer incidence of the host country </li></ul>
  11. 11. ETIOLOGY: <ul><li>Precancerous conditions: </li></ul><ul><ul><li>Leucoplakia </li></ul></ul><ul><ul><li>Actinic keratosis </li></ul></ul><ul><ul><li>Polyps of colon & rectum </li></ul></ul><ul><ul><li>Neurofibromas </li></ul></ul><ul><ul><li>Dysplasia of cervix, bronchial </li></ul></ul><ul><ul><li>Chronic ulcerative colitis </li></ul></ul><ul><li>Hereditary factors: </li></ul><ul><ul><li>Familial polyposis – colonic CA </li></ul></ul><ul><ul><li>Breast CA – 2-3x in daughters and in younger age </li></ul></ul>
  12. 12. ETIOLOGY: <ul><li>Oncogenes & Growth Factors: </li></ul><ul><ul><li>RNA tumor viruses cause: </li></ul></ul><ul><ul><ul><li>Carcinomas </li></ul></ul></ul><ul><ul><ul><li>Sarcoma </li></ul></ul></ul><ul><ul><ul><li>Leukemia </li></ul></ul></ul><ul><ul><ul><li>Lymphomas </li></ul></ul></ul><ul><ul><li>Retrovirus have an enzyme that alters genomic RNA resulting to abnormal growth and differentiation of the cell. </li></ul></ul><ul><li>Multi-factorial: </li></ul><ul><ul><li>Lung / breast CA </li></ul></ul>
  13. 13. CANCER BIOLOGY <ul><li>Morphologic changes: </li></ul><ul><ul><li>Rise from a single cell </li></ul></ul><ul><ul><li>Revert to more primitive cell types </li></ul></ul><ul><ul><li>Normal orderly tissue patterns are lost or replaced by the random pilling up of malignant cells w/o definite pattern </li></ul></ul><ul><ul><li>High index of mitoses </li></ul></ul><ul><ul><li>Invasion of adjacent structures </li></ul></ul>
  14. 14. CANCER BIOLOGY <ul><li>Biochemical changes: </li></ul><ul><ul><li>Changes in DNA, RNA and chemical architecture results to LOSS of CONTACT INHIBITION to proliferation and intercellular adhesiveness </li></ul></ul><ul><ul><li>Reversion of normal cellular biochemistry to that of the embryonal cells that produces EMBRYONAL subs. (CEA, alpha fetoprotein) </li></ul></ul>
  15. 15. CANCER BIOLOGY <ul><li>Biochemical changes: </li></ul><ul><ul><li>Also produced biologically active subs. Normally produced by the cells. (hyperparathyroidism); also that are not normally produced by the cells of origin (bronchogenic CA=ACTH) </li></ul></ul><ul><li>Growth rates of neoplasm: </li></ul><ul><ul><li>Doubling time is doubled </li></ul></ul><ul><ul><li>Takes 30 doubling time to produce 1cm nodule </li></ul></ul>
  16. 16. CANCER BIOLOGY <ul><li>Effector mechanism in tumor immunity: </li></ul><ul><ul><li>Host provides a number of effector mechs. that destroys the tumor: </li></ul></ul><ul><ul><ul><li>Tumor-antigen-specific antibodies </li></ul></ul></ul><ul><ul><ul><li>Mononuclear phagocytes </li></ul></ul></ul><ul><ul><ul><li>Natural killer cells </li></ul></ul></ul><ul><ul><ul><li>Cytotoxic T lymphocytes </li></ul></ul></ul><ul><ul><ul><li>Neutrophils </li></ul></ul></ul><ul><ul><ul><li>K cells </li></ul></ul></ul>
  17. 17. CANCER BIOLOGY <ul><li>Effector mechanism in tumor immunity: </li></ul><ul><ul><li>Tumor Necrosis Factor (TNF): </li></ul></ul><ul><ul><ul><li>Cytokines produced by monocytes, machrophage, endothelial cells, large granular lymphocytes and neutrophils </li></ul></ul></ul><ul><ul><ul><li>Properties: </li></ul></ul></ul><ul><ul><ul><ul><li>Direct cytotoxicity for certain cells </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Stimulation of procoagulant activity by vascular endothelial cells </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Induction of fever by direct effect on the hypothalamic thermoregulatory center </li></ul></ul></ul></ul>
  18. 18. CANCER PATHOLOGY <ul><li>Classification of Neoplasm: </li></ul><ul><ul><li>Carcinoma – arising from epithelial cells </li></ul></ul><ul><ul><li>Sarcoma – arise from connective tissue and cells of mesenchymal origin (fibrous, muscular, fatty, vascular & skeletal). </li></ul></ul>
  19. 19. CANCER PATHOLOGY <ul><li>Grading of malignancy: </li></ul><ul><ul><li>Broders classified carcinoma into 4 grades according to: </li></ul></ul><ul><ul><ul><li>Degree of differentiation </li></ul></ul></ul><ul><ul><ul><li>Appearance of cells, their nuclei and the number of mitotic figures </li></ul></ul></ul><ul><ul><li>Grade I – least malignant </li></ul></ul><ul><ul><li>Grade IV – most malignant </li></ul></ul>
  20. 20. CANCER PATHOLOGY <ul><ul><li>Carcinoma in Situ: </li></ul></ul><ul><ul><ul><li>Has cytologic characteristic of malignant tumors but w/ no detectable invasion into the surrounding tissue or infiltration into deeper cell layers </li></ul></ul></ul>
  21. 21. ROUTES OF SPREAD: <ul><li>Metastasis may entirely dominate the clinical picture, while the primary tumor remains latent and asymptomatic </li></ul><ul><ul><li>Direct extension </li></ul></ul><ul><ul><li>Lymphatic spread </li></ul></ul><ul><ul><ul><li>Common in epithelial neoplasms of all types (except for basal cell CA) </li></ul></ul></ul>
  22. 22. ROUTES OF SPREAD: <ul><li>Vascular spread </li></ul><ul><ul><li>Either thru the thoracic duct or by the invasion of blood vessels </li></ul></ul><ul><ul><li>Capillaries are almost invaded, veins invaded frequently but arteries rarely. </li></ul></ul><ul><ul><li>More common in sarcomas </li></ul></ul><ul><li>Spread through serous cavities </li></ul><ul><ul><li>Peritoneal seedings (gastrointestinal CA) </li></ul></ul>
  23. 23. CLINICAL MANIFESTATION : <ul><li>The onset of neoplastic state is difficult to date (asymptomatic). </li></ul><ul><ul><li>Seven Danger Signals of Cancer (Direct manifestation): </li></ul></ul><ul><ul><li>Change in bowel or bladder habits </li></ul></ul><ul><ul><li>A sore that does not heal </li></ul></ul><ul><ul><li>Unusual bleeding or discharge </li></ul></ul><ul><ul><li>Thickening or lump in breast or elsewhere </li></ul></ul><ul><ul><li>Indigestion or difficult in swallowing </li></ul></ul><ul><ul><li>Obvious change in wart or mole </li></ul></ul><ul><ul><li>Nagging cough or hoarseness </li></ul></ul>
  24. 24. CLINICAL MANIFESTATION : <ul><li>Indirect or Systemic Manifestation : </li></ul><ul><ul><li>Secondary to metastasis </li></ul></ul><ul><ul><ul><li>Cachexia </li></ul></ul></ul><ul><ul><li>Secondary to none metastatic: </li></ul></ul><ul><ul><ul><li>Ectopic production of known hormones </li></ul></ul></ul><ul><ul><ul><li>Secretion of unidentified, hormone like substances </li></ul></ul></ul><ul><ul><ul><li>Toxic substances secreted from the tumor </li></ul></ul></ul><ul><ul><ul><li>Autoimmune – host is sensitized to an antigen from the tumor </li></ul></ul></ul>
  25. 25. CLINICAL MANIFESTATION : <ul><li>Signs of Expansile growth: </li></ul><ul><li>Obstruction </li></ul><ul><li>Destruction </li></ul><ul><li>Signs of Infiltrative Growth: </li></ul><ul><ul><li>Tumor infiltrates the nerves </li></ul></ul><ul><li>Pain </li></ul><ul><li>Numbness </li></ul><ul><li>paralysis </li></ul>
  26. 26. CLINICAL MANIFESTATION : <ul><li>Signs of Tumor necrosis (Bleeding & Infection): </li></ul><ul><ul><li>Tumor may become necrotic, ulcerate and bleed </li></ul></ul><ul><ul><li>Fatigue and weakness in right colon cancer due to anemia </li></ul></ul><ul><ul><li>Inflammation caused by cecal CA can mimic the clinical symptoms of acute AP or cholecystitis. </li></ul></ul><ul><li>Unknown primary tumors presenting as metastases </li></ul>
  27. 27. DIAGNOSIS OF CANCER: <ul><li>Clinical History: </li></ul><ul><ul><li>Warning signs for Cancer: </li></ul></ul><ul><ul><li>Weight loss </li></ul></ul><ul><ul><li>Loss of Appetite </li></ul></ul><ul><ul><li>Bleeding or a discharge from any body orifice or nipple </li></ul></ul><ul><ul><li>Sore that is slow to heal </li></ul></ul>
  28. 28. DIAGNOSIS OF CANCER: <ul><li>Clinical History: </li></ul><ul><ul><li>Warning signs for Cancer: </li></ul></ul><ul><ul><li>Persistent cough or wheeze </li></ul></ul><ul><ul><li>Change in voice </li></ul></ul><ul><ul><li>Difficulty of swallowing </li></ul></ul><ul><ul><li>Change in bowel habit </li></ul></ul><ul><ul><li>Growing lump in the skin, breast, abdomen or muscle </li></ul></ul>
  29. 29. DIAGNOSIS OF CANCER: <ul><li>Physical Examination: </li></ul><ul><ul><li>Palpable masses (movable, non-movable) </li></ul></ul><ul><ul><li>LN enlargement </li></ul></ul><ul><li>Laboratory Examination: </li></ul><ul><ul><li>Blood examination </li></ul></ul><ul><ul><li>Radiological procedure: </li></ul></ul><ul><ul><ul><li>X-ray, esophagoram, Barium enema, mammography, thyroid scan, CT scan, MRI </li></ul></ul></ul>
  30. 30. DIAGNOSIS OF CANCER: <ul><li>Laboratory Examination: </li></ul><ul><ul><li>Endoscopy: </li></ul></ul><ul><ul><ul><li>Bronchoscopy, esophagoscopy, gastroscopy, proctosigmoidoscopy, colonoscopy, cystoscopy </li></ul></ul></ul>
  31. 31. DIAGNOSIS OF CANCER: <ul><li>Laboratory Examination: </li></ul><ul><ul><li>Biopsy: </li></ul></ul><ul><ul><ul><li>To document presence of malignancy </li></ul></ul></ul><ul><ul><ul><li>Types: </li></ul></ul></ul><ul><ul><ul><ul><li>Needle biopsy (cytological) </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Incisional biopsy </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Excisional biopsy </li></ul></ul></ul></ul><ul><ul><ul><li>Rapid frozen biopsy / exfoliative cytology (Pap smear) </li></ul></ul></ul>
  32. 32. STAGING OF CANCER: <ul><li>Clinical Staging of Cancer: </li></ul><ul><ul><li>TNM: </li></ul></ul><ul><li>Stage I = cancer confined to it’s primary site </li></ul><ul><li>Stage II = more locally advanced disease </li></ul><ul><li>Stage III = metastasis to regional LN </li></ul><ul><li>Stage IV = metastasis to distant sites </li></ul><ul><ul><li>Use all information available prior to 1 st definitive treatment: </li></ul></ul>
  33. 33. STAGING OF CANCER: <ul><li>Post-surgical Resection Staging: </li></ul><ul><ul><li>Pathological Staging: </li></ul></ul><ul><ul><ul><li>The extent of disease using all data available at the time of surgery and on examination of a completely resected specimen. </li></ul></ul></ul><ul><li>Re-treatment Staging: </li></ul><ul><ul><li>Restaging is necessary for additional or secondary definitive treatment after a (disease-free) interval following 1 st treatment. </li></ul></ul><ul><li>Autopsy Staging: </li></ul><ul><ul><li>Used only when the cancer is 1 st diagnosed at autopsy. </li></ul></ul>
  34. 34. CANCER TREATMENT: <ul><li>Interdisciplinary Approach: </li></ul><ul><ul><li>Surgical resection 55% (40% alone) </li></ul></ul><ul><ul><li>Radiation therapy 34% (16% alone) </li></ul></ul><ul><ul><li>Chemotherapy 22% (alone or combination) </li></ul></ul><ul><li>Surgery & radiation tx represents treatment of cancers that remains localized to it’s primary site or regional LN. </li></ul><ul><li>Chemotherapy and Immunotherapy – tx effective against tumor cells already metastatic to distant organ sites. </li></ul>
  35. 35. CANCER TREATMENT: <ul><li>GOALS of Therapy: </li></ul><ul><li>Vary w/ extent of the cancer : </li></ul><ul><ul><li>Localized w/o evidence of spread: </li></ul></ul><ul><ul><ul><li>Eradicate the cancer and CURE THE PATIENT </li></ul></ul></ul><ul><ul><li>Spread beyond the local site: </li></ul></ul><ul><ul><ul><li>Control patient’s symptoms and to maintain maximum activity for the longest possible period of time. </li></ul></ul></ul>
  36. 36. CANCER TREATMENT: <ul><li>CRITERIA of Incurability: </li></ul><ul><li>Distant metastasis (most common) </li></ul><ul><li>Evidence of extensive local infiltration of adjacent organs or structures </li></ul><ul><ul><li>Pt’s general condition and the presence of any co-existing disease must be considered in planning therapy. </li></ul></ul><ul><ul><li>The PSYCHOLOGICAL makeup of the patient and the patient’s life situation must be considered. </li></ul></ul>
  37. 37. CANCER TREATMENT: <ul><li>SURGICAL RESECTION: </li></ul><ul><li>Surgical Curative Resection: </li></ul><ul><ul><li>Wide local resection: </li></ul></ul><ul><ul><ul><li>Low grade malignancy </li></ul></ul></ul><ul><ul><ul><li>Basal cell CA of the skin </li></ul></ul></ul><ul><ul><li>Radical Local Resection: </li></ul></ul><ul><ul><ul><li>High grade malignancy </li></ul></ul></ul><ul><ul><ul><li>En Bloc LN dissection for breast, esophagus, gastric, colorectal CA </li></ul></ul></ul><ul><li>Surgical Palliative Resection: </li></ul><ul><ul><li>To relieve symptoms </li></ul></ul><ul><ul><li>To prolong a useful comfortable life </li></ul></ul><ul><ul><li>Gastrojejunostomy, colostomy </li></ul></ul>
  38. 38. CANCER TREATMENT: <ul><li>RADIOTHERAPY: </li></ul><ul><ul><li>Destroy tumor with preservation of anatomic structures </li></ul></ul><ul><ul><li>Direct toxic effect to cells due to ionization of water </li></ul></ul>
  39. 39. CANCER TREATMENT: <ul><li>CHEMOTHERAPY: </li></ul><ul><ul><li>Antimetabolites: </li></ul></ul><ul><ul><ul><li>Inhibit enzymes of nucleic acid synthesis </li></ul></ul></ul><ul><ul><ul><li>Methotrexate & 5-FU </li></ul></ul></ul><ul><ul><li>Alkylating agents: </li></ul></ul><ul><ul><ul><li>Substitute alkyl grp for the hydrogen atom </li></ul></ul></ul><ul><ul><ul><li>Alkylation of DNA molecule interferes with replication in transcription </li></ul></ul></ul>
  40. 40. CANCER TREATMENT: <ul><li>CHEMOTHERAPY: </li></ul><ul><ul><li>Antibiotics: </li></ul></ul><ul><ul><ul><li>From soil fungi </li></ul></ul></ul><ul><ul><ul><li>Forms stable complexes with DNA and inhibit synthesis of DNA and RNA </li></ul></ul></ul><ul><ul><ul><li>Actinomycin D, Doxorubicin, Bleomycin </li></ul></ul></ul><ul><ul><li>Vinca Alkaloids: </li></ul></ul><ul><ul><ul><li>Bind to microtubular proteins necessary for cell division causing cell death during mitosis </li></ul></ul></ul><ul><ul><ul><li>Vincristine & Vinblastine </li></ul></ul></ul>
  41. 41. CANCER TREATMENT: <ul><li>IMMUNOTHERAPY: </li></ul><ul><ul><li>Inhibit proliferation of cancer cells w/o affecting function of normal cells </li></ul></ul><ul><ul><li>Stimulates the host to generate specific immune response to its tumor-vaccine from tumor cells </li></ul></ul><ul><ul><li>TUMOR SPECIFIC ANTISERUM: </li></ul></ul><ul><ul><ul><li>Murine monoclonal antibodies </li></ul></ul></ul><ul><ul><ul><li>Immunotoxins </li></ul></ul></ul><ul><ul><li>None-specific immunotherapy=BCG vaccine </li></ul></ul>
  42. 42. PROGNOSIS: <ul><li>DETERMINANTS: </li></ul><ul><ul><li>Site of origin of primary tumor </li></ul></ul><ul><ul><li>Stage of the disease </li></ul></ul><ul><ul><li>Histologic features of the cancer </li></ul></ul><ul><ul><li>Host immune factors </li></ul></ul><ul><ul><li>Age of the patients </li></ul></ul>
  43. 43. THANK YOU

×